Learn About Familial Prostate Cancer

View Main Condition: Prostate Cancer

What is the definition of Familial Prostate Cancer?
Familial prostate cancer is a cluster of prostate cancer within a family. Most cases of prostate cancer occur sporadically in people with no family history of the condition. However, approximately 5% to 10% of prostate cancer cases are believed to be primarily caused by a genetic predisposition to the condition. In many families, the underlying genetic cause is unknown; however, some of these cases are caused by changes in the BRCA1, BRCA2, HOXB13, or several other genes. Other cases are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle. High-risk cancer screening at an earlier age is typically recommended in men who have an increased risk for prostate cancer based on personal and/or family histories.
Save information for later
Sign Up
What are the alternative names for Familial Prostate Cancer?
  • Familial prostate cancer
  • Hereditary prostate cancer
  • Prostate cancer, familial
  • Prostate cancer, hereditary
Who are the top Familial Prostate Cancer Local Doctors?
AA
Dr. Andrew J. Armstrong
Oncology
Elite
Highly rated in
17
conditions
Oncology

Duke Health

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 

Andrew Armstrong is an Oncologist in Durham, North Carolina. Armstrong has been practicing medicine for over 23 years and is rated as an Elite expert by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 17 other conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Prostatectomy. He is licensed to treat patients in North Carolina. Armstrong is currently accepting new patients.

ES
Dr. Edward M. Schaeffer
Urology
Elite
Highly rated in
9
conditions
Urology

Northwestern Medicine

Northwestern Medicine Urology

675 N Saint Clair St, 
Chicago, IL 

Edward Schaeffer is an Urologist in Chicago, Illinois. Schaeffer has been practicing medicine for over 22 years and is rated as an Elite expert by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 9 other conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Urinary Tract Infection (UTI), Prostatectomy, and Vasectomy. He is licensed to treat patients in Maryland. Schaeffer is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn more
SE
Dr. Scott E. Eggener
Urology
Elite
Highly rated in
24
conditions
Urology

UChicago Medicine

Duchossois Center For Advanced Medicine (DCAM) - Hyde Park

5758 S Maryland Ave, 
Chicago, IL 

Scott Eggener is an Urologist in Chicago, Illinois. Eggener has been practicing medicine for over 24 years and is rated as an Elite expert by MediFind in the treatment of Familial Prostate Cancer. He is also highly rated in 24 other conditions, according to our data. His top areas of expertise are Prostate Cancer, Testicular Cancer, Familial Prostate Cancer, Prostatectomy, and Orchiectomy. He is licensed to treat patients in Illinois. Eggener is currently accepting new patients.

View All Doctors
What are the latest Familial Prostate Cancer Clinical Trials?
The Main Agricultural Health Study - A Prospective Study of Cancer and Other Diseases Among Men and Women in Agriculture
Enrollment Status: Active, not recruiting
Publish Date: December 14, 2022

Summary: The Agricultural Health Study (AHS) is a collaborative effort between the National Cancer Institute and the National Institute of Environmental Health Sciences. The U.S. Environmental Protection Agency and the National Institute for Occupational Safety and Health are providing support for a limited exposure assessment effort. Initial data collection on a prospective cohort of 89,658 study subjects...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
Enrollment Status: Recruiting
Publish Date: December 14, 2022

Summary: This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop leiomy...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Familial Prostate Cancer?
Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study.
Condition: Localized Prostate Cancer
Journal: The Journal of urology
Treatment Used: External Beam Radiotherapy with Low Dose Rate Brachytherapy Boost vs. Radical Prostatectomy
Number of Patients: 112
Published: August 25, 2022
Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.
Condition: Prostate Cancer Biochemical Recurrence
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Treatment Used: Surveillance, Salvage Radiation, and Androgen Deprivation Therapy (ADT)
Number of Patients: 0
Published: May 03, 2022
Tired of the same old research?
Check Latest Advances
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Treatment Used: Ribociclib in Combination with Docetaxel plus Prednisone
Number of Patients: 43
Published: February 17, 2022
View All Latest Advances